HBO1は白血病の幹細胞を維持するために必要です.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。研究者は,HBO1を急性骨髄性白血病 (AML) の白血病幹細胞維持の重要なレギュラーとして特定しました. 新種の小分子でHBO1を抑制すると,患者由来AML細胞に有効性が示され,新しい治療戦略が提供されました.
科学分野
- 血液学
- 分子生物学
- エピジェネティクス
背景
- 急性骨髄性白血病 (AML) は,転写不調によって引き起こされる複雑な血液がんです.
- 現在のエピジェネティック療法では 白血病幹細胞 (LSC) を根絶できず,治療の有効性を制限しています.
研究 の 目的
- 標的治療のためのLSCにおける新しい依存性を特定する.
- LSCの維持におけるクロマチン調節体の役割を調査する.
主な方法
- ex vivo LSC マウスモデルにおけるクロマチン調節体を標的とする小型のヘアピンRNAのスクリーニング.
- CRISPR領域のスクリーニングと定量質スペクトロメトリー
- 小分子HBO1阻害剤の開発と試験
主要な成果
- HBO1 (MYSTアセチルトランスフェラーゼ) とその複合体は,LSCの維持に重要なものとして特定されました.
- HBO1のヒストンアセチルトランスフェラーゼドメインは,H3K14acにとって不可欠であり,LSCにおける重要な遺伝子発現 (Hoxa9,Hoxa10) を維持する.
- HBO1抑制はヒトのAML細胞系と患者細胞で有効性を示した.
結論
- HBO1はAMLにおけるLSCの根絶に不可欠な治療標的である.
- 新種の小分子HBO1阻害剤は,AML治療における臨床転移の有望性を示しています.
自動的に一致したビデオです Contact us もしそれらが関連していない場合
自動的に一致したビデオです Contact us もしそれらが関連していない場合
関連する概念動画
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Commitment is the process whereby stem cells:
lose their ability to form all cell types and
irreversibly change into a specific type.
The multipotent hematopoietic stem cells, (HSCs), differentiate into the multipotent hematopoietic progenitor cells, (HPCs). The HPCs express many lineage-specific cytokine receptors. Each of these receptors binds specific cytokines, activates distinct signaling pathways, and expresses a particular gene set. The HPCs further differentiate to...
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...